Beta Bionics, Inc.
A medical device company that develops automated insulin delivery systems for people with diabetes. Its flagship product is the iLet bionic pancreas, a device that uses an algorithm to automatically manage blood sugar levels. The company was founded by biomedical engineer Ed Damiano, who was inspired to build the device after his son was diagnosed with type 1 diabetes.
Sold 23.5K
Sold 16.5K
Sold 6.3K
Granted 59.9K · Sold 69.6K
Granted 16.2K · Sold 29.2K
Granted 21.0K
Granted 21.0K
Granted 21.0K
Granted 21.0K · Sold 2.8K
Granted 21.0K · Sold 4.8K
Granted 21.0K · Sold 6.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Saint SeanPresident & CEO, Director · 3 transactions | +301.4% | 420.9K | — | — | 23.5K |
| Mensinger MikeChief Product Officer · 6 transactions | +98.3% | 184.4K | — | — | 16.5K |
| Russell Steven JonChief Medical Officer · 3 transactions | +141.3% | 173.8K | — | — | 6.3K |
| Feider StephenChief Financial Officer · 19 transactions | +275.4% | 170.8K | 59.9K | — | 69.6K |
| Hopman MarkChief Commercial Officer · 12 transactions | +157.2% | 129.4K | 16.2K | — | 29.2K |
| Michel Gerard JDirector · 2 transactions | +167.1% | 33.5K | 21.0K | — | — |
| Carney SeanDirector · 2 transactions | +186.4% | 32.2K | 21.0K | — | — |
| Dearen Danny L.Director · 2 transactions | +186.4% | 32.2K | 21.0K | — | — |
| Palasis MariaDirector · 6 transactions | +161.4% | 29.4K | 21.0K | — | 2.8K |
| Lezack AdamDirector · 8 transactions | +143.6% | 27.4K | 21.0K | — | 4.8K |
| Jones ChristyDirector · 5 transactions | +131.1% | 26.0K | 21.0K | — | 6.2K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -158.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.